With the development of science and technology and the advancement of various favorable medical policies, new products and new dosage forms emerge in an endless stream, bringing broad development prospects to my country's pharmaceutical packaging market. The data shows that by the end of 2018, the market size of China's pharmaceutical packaging industry had reached 106.8 billion yuan, of which plastic packaging and composite material packaging accounted for 43.3% and 24.0% respectively. COP packaging has gradually replaced glass packaging and has become a high value-added packaging. drug of choice.
Pharmaceutical packaging refers to a processing process that uses appropriate materials or containers and uses packaging technology to divide (fill), seal, pack, and label semi-finished or finished pharmaceutical preparations to provide quality assurance, trademark identification, and instructions for pharmaceuticals. the general term for.
RTU(ready to use) 2ml COP vial
In the past two years, my country has introduced various policies to support the research and development of innovative drugs, especially some high-value-added drugs such as anti-tumor and lymphatic antigens, which have higher requirements for drug packaging, and CZ vials have low protein adsorption characteristics and low refractive index. Compared with glass bottles, it is more suitable for the packaging of such drugs due to its small size, stable chemical properties, and high light transmittance.
Pharmaceutical packaging is an inseparable part of medicines. Good packaging is crucial in meeting regulatory requirements, improving brand image and product competitiveness. The application of COP vial in the foreign pharmaceutical industry has become very common. Domestic enterprises must keep up with the development trend of the industry and persist in innovation in order to better seize development opportunities.
没有评论:
发表评论